Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported financial results for the second quarter ended June 30, 2014, and also provided an overview of certain corporate accomplishments and plans.
“We ended the second quarter with a cash, cash equivalents and investments balance of $104.4 million which we expect will fund our clinical programs into the first half of 2016,” said Robert Forrester, President and Chief Executive Officer of Verastem.
Help employers find you! Check out all the jobs and post your resume.
